Dilated cardiomyopathy
Drug research and approvals for dilated cardiomyopathy: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 22, 2026, 56 studies of dilated cardiomyopathy are recruiting on ClinicalTrials.gov, Health Canada has authorized 2 drug trials for it since 2013, and FDA has 1 approved and 3 open orphan designations naming it.
- Recruiting worldwide: 56
- Trials authorized in Canada: 2
- FDA orphan approvals: 1
- EU medicines: 0
- Multimodal Assessment of Remodeling and Stratification in Heart FailureNCT07940868 · Not reported · Shandong Provincial Hospital · starts Dec 1, 2022
- A Study of the Long-term Safety and Efficacy of Danicamtiv in Adults With Symptomatic Genetic and Familial Dilated…NCT07771465 · Phase 3 · Kardigan, Inc. · starts Aug 26, 2026
- the Clinical Outcome of Empagliflozin in Pediatric Heart Failure PatientsNCT07692256 · Phase 2 · Ain Shams University · starts Dec 1, 2025
- Observational Study of Natural History of BAG3 Gene Mutation-Associated Dilated Cardiomyopathy in Chinese AdultsNCT07646600 · Not reported · AstraZeneca · starts Aug 18, 2026
- A Study With NVC-001 in Patients With LMNA-related Dilated Cardiomyopathy (SUNBEAM-LMNA)NCT07606274 · Phase 1 / Phase 2 · Nuevocor Pte. Ltd. · starts Jun 16, 2026
- Cardiac Magnetic Resonance-Clinical Prediction Model-Dilated CardiomyopathyNCT07527715 · Not reported · Shandong Provincial Hospital · starts Dec 1, 2021
- Safety and Efficacy of Second Infusion of FAP iCDC in End-stage Dilated CardiomyopathyNCT07516288 · Phase 1 · Second Affiliated Hospital, Zhejiang University, School of Medicine · starts May 11, 2026
- RHYthm and Myocardial Function Relationship Evaluation in Heart DiseasesNCT07491237 · Not reported · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · starts Jun 23, 2026
- An AAV Gene Therapy Trial of AFTX-201 in Adults With BAG3-Associated Dilated Cardiomyopathy (DCM)NCT07426419 · Phase 1 / Phase 2 · Affinia Therapeutics · starts Dec 1, 2026
Phase 3 6
- ARRY-797MAP kinase p38 alpha inhibitor
- EnalaprilatAngiotensin-converting enzyme inhibitor
- PerindoprilAngiotensin-converting enzyme inhibitor
- RosuvastatinHMG-CoA reductase inhibitor
- CandesartanType-1 angiotensin II receptor antagonist
- Resveratrol
Phase 2 7
- Ixmyelocel-t
- FilgrastimGranulocyte colony stimulating factor receptor agonist
- RanolazineSodium channel protein type V alpha subunit blocker
- SimvastatinHMG-CoA reductase inhibitor
- DanicamtivCardiac myosin activator
- Honey
- Mitoquinone cation
How its trials ended
238 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 41 whose ending is known, 34% met their primary endpoint, 5% missed it and 61% stopped early.
- Completed, result not reported7833%
- Ongoing6527%
- Status unknown5423%
- Met its primary endpoint146%
- Stopped: other or unclear146%
- Stopped: sponsor or business decision52%
- Stopped: enrollment or feasibility42%
- Missed its primary endpoint21%
- Stopped: safety1<1%
- Stopped: funding1<1%
| May 25, 2018 | A phase 3, multinational, randomized, placebo-controlled study of ARRY-371797 in patients with symptomatic dilated cardiomyopathy due to a lamin a/c gene…ARRY-371797 (PF-07265803) | Pfizer | Ongoing |
| Sep 13, 2013 | "a multicentre, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy, safety and tolerability of transendocardial…Ixmyelocel-t | Aastrom Biosciences, Inc. | Pending |
| Apr 22, 2019 | CorlanorCorlanor is indicated for the treatment of stable symptomatic heart failure due to dilated cardiomyopathy (DCM) in pediatric patients aged… | Amgen, Inc., | Approved |
| Jul 16, 2026 | A non-replication recombinant adeno-associated virus (AAV)…Treatment of dilated cardiomyopathy due to mutations in the BAG3 gene | Affinia Therapeutics | Designated |
| Oct 30, 2018 | TrimetazidineTreatment of dilated cardiomyopathy | Martin Pharmaceuticals, Inc. | Designated |
| Nov 19, 2015 | VasomeraTreatment of cardiomyopathy associated with dystrophinopathies; Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy BMD), and… | ImmunoForge Co. Ltd. | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA